Abstract:Study Design.
Multi-center, retrospective cohort study.
Objective.
To determine the epidemiology, identify predictors of early mortality, and develop predictive models for traumatic spinal cord injury (SCI).
Summary of Background Data.
Despite improved initial care and management strategies, traumatic SCI remains a devastating event. Knowledge of the epidemiological state and predictive factors for mortality… Show more
“…The reported mortality rate of 6.2% parallels with information from comparable monocentric studies in Canada (5.7% 15 ), Iceland (6.3% 20 ) and the United States (6.6% 7 ) and is also in the range of large nationwide epidemiological datasets (6.6%–7.5% 21 , 5.7% 22 ), although the length of stay (LOS) of our cohort is expanded compared to most other studies, as it covers acute and early chronic rehabilitation phase. Patient characteristics reflect the changing epidemiology of tSCI in high income countries with an increase of fall related injuries of patients with high age and more frequent and multiple comorbid conditions.…”
Comorbidity scores are important predictors of in-hospital mortality after traumatic spinal cord injury (tSCI), but the impact of specific pre-existing diseases is unknown. This retrospective cohort study aims at identifying relevant comorbidities and explores the influence of end-of-life decisions. In-hospital mortality of all patients admitted to the study center after acute tSCI from 2011 to 2017 was assessed. A conditional inference tree analysis including baseline data, injury characteristics, and Charlson Comorbidity Index items was used to identify crucial predictors. End-of-life decisions were recorded. Three-hundred-twenty-one patients were consecutively enrolled. The median length of stay was 95.7 days (IQR 56.8–156.0). During inpatient care, 20 patients (6.2%) died. These patients were older (median: 79.0 (IQR 74.7–83.2) vs. 55.5 (IQR 41.4–72.3) years) and had a higher Charlson Comorbidity Index score (median: 4.0 (IQR 1.75–5.50) vs. 0.0 (IQR 0.00–1.00)) compared to survivors. Pre-existing kidney or liver disease were identified as relevant predictors of in-hospital mortality. End-of-life decisions were observed in 14 (70.0%) cases. The identified impairment of kidney and liver, important for drug metabolism and elimination, points to the need of careful decisions on pharmaceutical treatment regimens after tSCI. Appropriate reporting of end-of-life decisions is required for upcoming studies.
“…The reported mortality rate of 6.2% parallels with information from comparable monocentric studies in Canada (5.7% 15 ), Iceland (6.3% 20 ) and the United States (6.6% 7 ) and is also in the range of large nationwide epidemiological datasets (6.6%–7.5% 21 , 5.7% 22 ), although the length of stay (LOS) of our cohort is expanded compared to most other studies, as it covers acute and early chronic rehabilitation phase. Patient characteristics reflect the changing epidemiology of tSCI in high income countries with an increase of fall related injuries of patients with high age and more frequent and multiple comorbid conditions.…”
Comorbidity scores are important predictors of in-hospital mortality after traumatic spinal cord injury (tSCI), but the impact of specific pre-existing diseases is unknown. This retrospective cohort study aims at identifying relevant comorbidities and explores the influence of end-of-life decisions. In-hospital mortality of all patients admitted to the study center after acute tSCI from 2011 to 2017 was assessed. A conditional inference tree analysis including baseline data, injury characteristics, and Charlson Comorbidity Index items was used to identify crucial predictors. End-of-life decisions were recorded. Three-hundred-twenty-one patients were consecutively enrolled. The median length of stay was 95.7 days (IQR 56.8–156.0). During inpatient care, 20 patients (6.2%) died. These patients were older (median: 79.0 (IQR 74.7–83.2) vs. 55.5 (IQR 41.4–72.3) years) and had a higher Charlson Comorbidity Index score (median: 4.0 (IQR 1.75–5.50) vs. 0.0 (IQR 0.00–1.00)) compared to survivors. Pre-existing kidney or liver disease were identified as relevant predictors of in-hospital mortality. End-of-life decisions were observed in 14 (70.0%) cases. The identified impairment of kidney and liver, important for drug metabolism and elimination, points to the need of careful decisions on pharmaceutical treatment regimens after tSCI. Appropriate reporting of end-of-life decisions is required for upcoming studies.
“…We also graphically examined the association between the SCIRS and ISS (see Supplementary Figure S5). Results showed a positive correlation between the SCIRS and ISS scores (Pearson's correlation = 0.30, p<0.05) which supported the validity of the SCIRS given that ISS is a well-known index that has previously been used in tSCI research [11,[35][36][37]. This figure also demonstrates that the SCIRS is more sensitive than ISS in measuring mortality in the datasets.…”
Section: Validation Of Scirssupporting
confidence: 67%
“…Developing a predictive model of mortality is challenging due to the complex interactions of factors that contribute to patient outcomes. Regression models based on the generalized linear model have previously been used to develop prediction tools in several clinical studies [11][12][13]38,39]. Although these models have the benefit of simplicity with readily-available and interpretable parameters, they may fail to appreciate the potential interaction and complex behaviour of variables that is often present in biological conditions [32].…”
Section: Discussionmentioning
confidence: 99%
“…It is also essential for informing discussions with patients and their families, especially when the benefits of surgical intervention are uncertain and end-of-life care is contemplated [8][9][10]. Many studies have previously identified predictive factors and algorithms for assessing mortality risk following tSCI, however, no prognostic tool specific to the tSCI patient population is readily available for use in a clinical setting [2,3,[11][12][13]. In addition to the value that a predictive tool can provide for clinical decision-making and discussions with patients and families, it can also be used in clinical research to adjust for the potential impact of specific patient and injury characteristics on a study participant's risk of mortality.…”
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
“…Spinal cord injury (SCI) is a severely debilitating condition leading to neurological dysfunction, loss of independence, respiratory failure, psychological morbidities, and an increased lifelong mortality rate (Marion et al, 2017; Satkunendrarajah et al, 2018; Shibahashi et al, 2018; Wang et al, 2018b). In the United States, approximately 288,000 individuals are estimated to suffer from symptoms caused by SCI, and a recent survey showed the annual incidence of SCI is approximately 54 cases per one million people (Fehlings et al, 2018).…”
Significant progress has been made in the treatment of spinal cord injury (SCI). Advances in post-trauma management and intensive rehabilitation have significantly improved the prognosis of SCI and converted what was once an “ailment not to be treated” into a survivable injury, but the cold hard fact is that we still do not have a validated method to improve the paralysis of SCI. The irreversible functional impairment of the injured spinal cord is caused by the disruption of neuronal transduction across the injury lesion, which is brought about by demyelination, axonal degeneration, and loss of synapses. Furthermore, refractory substrates generated in the injured spinal cord inhibit spontaneous recovery. The discovery of the regenerative capability of central nervous system neurons in the proper environment and the verification of neural stem cells in the spinal cord once incited hope that a cure for SCI was on the horizon. That hope was gradually replaced with mounting frustration when neuroprotective drugs, cell transplantation, and strategies to enhance remyelination, axonal regeneration, and neuronal plasticity demonstrated significant improvement in animal models of SCI but did not translate into a cure in human patients. However, recent advances in SCI research have greatly increased our understanding of the fundamental processes underlying SCI and fostered increasing optimism that these multiple treatment strategies are finally coming together to bring about a new era in which we will be able to propose encouraging therapies that will lead to appreciable improvements in SCI patients. In this review, we outline the pathophysiology of SCI that makes the spinal cord refractory to regeneration and discuss the research that has been done with cell replacement and biomaterial implantation strategies, both by itself and as a combined treatment. We will focus on the capacity of these strategies to facilitate the regeneration of neural connectivity necessary to achieve meaningful functional recovery after SCI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.